<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Ciclosporin: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i499.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i499.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i499.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i1160.htm" title="Previous: Certolizumab pegol">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i940.htm" title="Next: Cilostazol">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i499">Ciclosporin</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Ciclosporin</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i2.htm" name="_2">ACE Inhibitors</a></td><td class="cBV"><b>increased risk of hyperkalaemia when  ciclosporin given with ACE inhibitors </b></td><td></td></tr><tr><td><a href="41001i551.htm">Acetazolamide</a></td><td class="cBV"><b>plasma concentration of  ciclosporin possibly increased by acetazolamide </b></td><td></td></tr><tr><td><a href="41001i392.htm" name="_392">Aciclovir</a></td><td>increased risk of nephrotoxicity when  ciclosporin given with aciclovir </td><td>Interactions do not apply to topical aciclovir preparations</td></tr><tr><td><a href="41001i1099.htm" name="_1099">Aliskiren</a></td><td class="cBV"><b> ciclosporin increases plasma concentration of aliskiren—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i22.htm">Allopurinol</a></td><td>plasma concentration of  ciclosporin possibly increased by allopurinol (risk of nephrotoxicity)</td><td></td></tr><tr><td><a href="41001i128.htm" name="_128">Aminoglycosides</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  ciclosporin given with aminoglycosides </b></td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td>plasma concentration of  ciclosporin possibly increased by amiodarone </td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i290.htm" name="_290">Amphotericin</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  ciclosporin given with amphotericin </b></td><td>Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</td></tr><tr><td><a href="41001i107.htm" name="_107">Angiotensin-II Receptor Antagonists</a></td><td class="cBV"><b>increased risk of hyperkalaemia when  ciclosporin given with angiotensin-II receptor antagonists </b></td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>plasma concentration of  ciclosporin possibly increased by atazanavir </b></td><td></td></tr><tr><td><a href="41001i596.htm" name="_596">Bezafibrate</a></td><td>increased risk of renal impairment when  ciclosporin given with bezafibrate </td><td></td></tr><tr><td><a href="41001i943.htm">Bosentan</a></td><td class="cBV"><b> ciclosporin increases plasma concentration of bosentan (also plasma concentration of ciclosporin reduced—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i277.htm" name="_277">Carbamazepine</a></td><td class="cBV"><b>metabolism of  ciclosporin accelerated by carbamazepine (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i445.htm">Carvedilol</a></td><td class="cBV"><b>plasma concentration of  ciclosporin increased by carvedilol </b></td><td></td></tr><tr><td><a href="41001i947.htm">Caspofungin</a></td><td class="cBV"><b> ciclosporin increases plasma concentration of caspofungin (manufacturer of caspofungin recommends monitoring liver enzymes)</b></td><td></td></tr><tr><td><a href="41001i158.htm">Chloramphenicol</a></td><td class="cBV"><b>plasma concentration of  ciclosporin possibly increased by chloramphenicol </b></td><td></td></tr><tr><td><a href="41001i335.htm">Chloroquine and Hydroxychloroquine</a></td><td class="cBV"><b>plasma concentration of  ciclosporin increased by chloroquine and hydroxychloroquine (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td class="cBV"><b>plasma concentration of  ciclosporin possibly increased by cimetidine </b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>metabolism of  ciclosporin inhibited by clarithromycin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i483.htm" name="_483">Colchicine</a></td><td class="cBV"><b>possible increased risk of nephrotoxicity and myotoxicity when  ciclosporin given with colchicine—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i1108.htm">Colesevelam</a></td><td class="cBV"><b>absorption of  ciclosporin reduced by colesevelam </b></td><td>Other drugs should be taken at least 4 hours before or after colesevelam to reduce possible interference with absorption </td></tr><tr><td><a href="41001i1120.htm" name="_1120">Dabigatran Etexilate</a></td><td class="cBV"><b> ciclosporin possibly increases plasma concentration of dabigatran etexilate—manufacturer of dabigatran etexilate advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i579.htm">Danazol</a></td><td class="cBV"><b>metabolism of  ciclosporin inhibited by danazol (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i1061.htm">Daptomycin</a></td><td class="cBV"><b>increased risk of myopathy when  ciclosporin given with daptomycin (preferably avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1076.htm" name="_1076">Darifenacin</a></td><td>avoidance of  ciclosporin advised by manufacturer of darifenacin </td><td></td></tr><tr><td><a href="41001i64.htm" name="_64">Diclofenac</a></td><td class="cBV"><b> ciclosporin increases plasma concentration of diclofenac (halve dose of diclofenac)</b></td><td></td></tr><tr><td><a href="41001i480.htm" name="_480">Digoxin</a></td><td class="cBV"><b> ciclosporin increases plasma concentration of digoxin (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td class="cBV"><b>plasma concentration of  ciclosporin increased by diltiazem </b></td><td></td></tr><tr><td><a href="41001i544.htm">Diuretics, Potassium-sparing and Aldosterone Antagonists</a></td><td class="cBV"><b>increased risk of hyperkalaemia when  ciclosporin given with potassium-sparing diuretics and aldosterone antagonists </b></td><td></td></tr><tr><td><a href="41001i525.htm">Diuretics, Thiazide and related</a></td><td>increased risk of nephrotoxicity and possibly hypermagnesaemia when  ciclosporin given with thiazides and related diuretics </td><td></td></tr><tr><td><a href="41001i516.htm" name="_516">Docetaxel</a></td><td><i>in vitro</i> studies suggest a possible interaction between  ciclosporin and docetaxel (consult docetaxel product literature)</td><td></td></tr><tr><td><a href="41001i506.htm">Doxorubicin</a></td><td class="cBV"><b>increased risk of neurotoxicity when  ciclosporin given with doxorubicin </b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td class="cBV"><b>plasma concentration of  ciclosporin possibly reduced by efavirenz </b></td><td></td></tr><tr><td><a href="41001i1030.htm" name="_1030">Epirubicin</a></td><td class="cBV"><b> ciclosporin increases plasma concentration of epirubicin </b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>metabolism of  ciclosporin inhibited by erythromycin (increased plasma concentration)</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i1031.htm" name="_1031">Etoposide</a></td><td> ciclosporin possibly increases plasma concentration of etoposide (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i1169.htm" name="_1169">Everolimus</a></td><td class="cBV"><b> ciclosporin increases plasma concentration of everolimus </b></td><td></td></tr><tr><td><a href="41001i970.htm" name="_970">Ezetimibe</a></td><td class="cBV"><b>plasma concentration of both drugs may increase when  ciclosporin given with ezetimibe </b></td><td></td></tr><tr><td><a href="41001i598.htm">Fenofibrate</a></td><td>increased risk of renal impairment when  ciclosporin given with fenofibrate </td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td class="cBV"><b>metabolism of  ciclosporin inhibited by fluconazole (increased plasma concentration)</b></td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>plasma concentration of  ciclosporin increased by fosamprenavir </b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td class="cBV"><b>plasma concentration of  ciclosporin increased by grapefruit juice (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i291.htm">Griseofulvin</a></td><td>plasma concentration of  ciclosporin possibly reduced by griseofulvin </td><td></td></tr><tr><td><a href="41001i1164.htm" name="_1164">Idarubicin</a></td><td class="cBV"><b> ciclosporin increases plasma concentration of idarubicin </b></td><td></td></tr><tr><td><a href="41001i933.htm">Imatinib</a></td><td>plasma concentration of  ciclosporin possibly increased by imatinib </td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>plasma concentration of  ciclosporin increased by indinavir </b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>metabolism of  ciclosporin inhibited by itraconazole (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>metabolism of  ciclosporin inhibited by ketoconazole (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i866.htm">Lanreotide</a></td><td>plasma concentration of  ciclosporin reduced by lanreotide </td><td></td></tr><tr><td><a href="41001i846.htm" name="_846">Lercanidipine</a></td><td class="cBV"><b>combination of  ciclosporin with lercanidipine may increase plasma concentration of either drug (or both)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i166.htm">Macrolides</a></td><td class="cBV"><b>metabolism of  ciclosporin possibly inhibited by macrolides (increased plasma concentration)</b></td><td><i>See also</i> Telithromycin</td></tr><tr><td><a href="41001i1142.htm" name="_1142">Mannitol</a></td><td>possible increased risk of nephrotoxicity when  ciclosporin given with mannitol </td><td></td></tr><tr><td><a href="41001i503.htm">Melphalan</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  ciclosporin given with melphalan </b></td><td></td></tr><tr><td><a href="41001i511.htm" name="_511">Methotrexate</a></td><td class="cBV"><b>risk of toxicity when  ciclosporin given with methotrexate </b></td><td></td></tr><tr><td><a href="41001i492.htm">Methylprednisolone</a></td><td class="cBV"><b>plasma concentration of  ciclosporin increased by high-dose methylprednisolone (risk of convulsions)</b></td><td></td></tr><tr><td><a href="41001i613.htm">Metoclopramide</a></td><td class="cBV"><b>plasma concentration of  ciclosporin increased by metoclopramide </b></td><td></td></tr><tr><td><a href="41001i1125.htm">Micafungin</a></td><td>plasma concentration of  ciclosporin possibly increased by micafungin </td><td></td></tr><tr><td><a href="41001i299.htm">Miconazole</a></td><td class="cBV"><b>metabolism of  ciclosporin possibly inhibited by miconazole (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i1173.htm" name="_1173">Mifamurtide</a></td><td>avoidance of  ciclosporin advised by manufacturer of mifamurtide </td><td></td></tr><tr><td><a href="41001i1165.htm" name="_1165">Mitoxantrone</a></td><td> ciclosporin reduces excretion of mitoxantrone (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i847.htm">Modafinil</a></td><td class="cBV"><b>plasma concentration of  ciclosporin reduced by modafinil </b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>plasma concentration of  ciclosporin possibly increased by nelfinavir </b></td><td></td></tr><tr><td><a href="41001i474.htm">Nicardipine</a></td><td class="cBV"><b>plasma concentration of  ciclosporin increased by nicardipine </b></td><td></td></tr><tr><td><a href="41001i475.htm" name="_475">Nifedipine</a></td><td> ciclosporin possibly increases plasma concentration of nifedipine (increased risk of toxicity including gingival hyperplasia)</td><td></td></tr><tr><td><a href="41001i60.htm" name="_60">NSAIDs</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  ciclosporin given with NSAIDs </b></td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i584.htm">Octreotide</a></td><td class="cBV"><b>plasma concentration of  ciclosporin reduced by octreotide </b></td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td>plasma concentration of  ciclosporin possibly increased by oestrogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td>plasma concentration of  ciclosporin possibly affected by omeprazole </td><td></td></tr><tr><td><a href="41001i856.htm">Orlistat</a></td><td class="cBV"><b>absorption of  ciclosporin possibly reduced by orlistat </b></td><td></td></tr><tr><td><a href="41001i900.htm">Oxcarbazepine</a></td><td>plasma concentration of  ciclosporin possibly reduced by oxcarbazepine </td><td></td></tr><tr><td><a href="41001i437.htm" name="_437">Phenobarbital</a></td><td class="cBV"><b>metabolism of  ciclosporin accelerated by phenobarbital (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i284.htm" name="_284">Phenytoin</a></td><td class="cBV"><b>metabolism of  ciclosporin accelerated by phenytoin (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i189.htm" name="_189">Polymyxins</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  ciclosporin given with polymyxins </b></td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b>metabolism of  ciclosporin inhibited by posaconazole (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i662.htm">Potassium Salts</a></td><td class="cBV"><b>increased risk of hyperkalaemia when  ciclosporin given with potassium salts </b></td><td>Includes salt substitutes</td></tr><tr><td><a href="41001i486.htm" name="_486">Prednisolone</a></td><td> ciclosporin increases plasma concentration of prednisolone </td><td></td></tr><tr><td><a href="41001i664.htm">Progestogens</a></td><td>plasma concentration of  ciclosporin possibly increased by progestogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i125.htm">Propafenone</a></td><td>plasma concentration of  ciclosporin possibly increased by propafenone </td><td></td></tr><tr><td><a href="41001i193.htm">Quinolones</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  ciclosporin given with quinolones </b></td><td></td></tr><tr><td><a href="41001i1147.htm" name="_1147">Ranolazine</a></td><td> ciclosporin possibly increases plasma concentration of ranolazine </td><td></td></tr><tr><td><a href="41001i855.htm" name="_855">Repaglinide</a></td><td> ciclosporin possibly enhances hypoglycaemic effect of repaglinide </td><td></td></tr><tr><td><a href="41001i201.htm" name="_201">Rifampicin</a></td><td class="cBV"><b>metabolism of  ciclosporin accelerated by rifampicin (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  ciclosporin possibly increased by ritonavir </b></td><td></td></tr><tr><td><a href="41001i974.htm">Rosuvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  ciclosporin given with rosuvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i791.htm" name="_791">Saquinavir</a></td><td class="cBV"><b>plasma concentration of both drugs increased when  ciclosporin given with saquinavir </b></td><td></td></tr><tr><td><a href="41001i1065.htm">Sevelamer</a></td><td>plasma concentration of  ciclosporin possibly reduced by sevelamer </td><td></td></tr><tr><td><a href="41001i921.htm" name="_921">Sirolimus</a></td><td> ciclosporin increases plasma concentration of sirolimus </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  ciclosporin reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i600.htm">Statins</a></td><td class="cBV"><b>increased risk of myopathy when  ciclosporin given with statins </b></td><td></td></tr><tr><td><a href="41001i206.htm">Sulfadiazine</a></td><td class="cBV"><b>plasma concentration of  ciclosporin possibly reduced by sulfadiazine </b></td><td></td></tr><tr><td><a href="41001i689.htm">Sulfinpyrazone</a></td><td class="cBV"><b>plasma concentration of  ciclosporin reduced by sulfinpyrazone </b></td><td></td></tr><tr><td><a href="41001i203.htm" name="_203">Sulfonamides</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  ciclosporin given with sulfonamides </b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b>plasma concentration of  ciclosporin increased by tacrolimus (increased risk of nephrotoxicity)—avoid concomitant use</b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of both drugs increased when  ciclosporin given with telaprevir (reduce dose of ciclosporin)</b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>plasma concentration of  ciclosporin possibly increased by telithromycin </b></td><td></td></tr><tr><td><a href="41001i292.htm">Terbinafine</a></td><td>plasma concentration of  ciclosporin possibly reduced by terbinafine </td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td>plasma concentration of  ciclosporin possibly increased by ticagrelor </td><td></td></tr><tr><td><a href="41001i217.htm">Trimethoprim</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  ciclosporin given with trimethoprim , also plasma concentration of ciclosporin reduced by <i>intravenous</i> trimethoprim</b></td><td></td></tr><tr><td><a href="41001i812.htm">Ursodeoxycholic Acid</a></td><td class="cBV"><b>absorption of  ciclosporin increased by ursodeoxycholic acid </b></td><td></td></tr><tr><td><a href="41001i218.htm" name="_218">Vancomycin</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  ciclosporin given with vancomycin </b></td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td class="cBV"><b>plasma concentration of  ciclosporin increased by verapamil </b></td><td></td></tr><tr><td><a href="41001i1134.htm">Vitamin E</a></td><td>plasma concentration of  ciclosporin possibly affected by vitamin E </td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>metabolism of  ciclosporin inhibited by voriconazole (increased plasma concentration)</b></td><td></td></tr></tbody></table></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i1160.htm">Previous: Certolizumab pegol</a> | <a class="top" href="41001i499.htm#">Top</a> | <a accesskey="]" href="41001i940.htm">Next: Cilostazol</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>